Sangamo Therapeutics Files for Chapter 11 Bankruptcy, Strikes Asset Deals with Eli Lilly and Astellas
The deals cover key gene therapy platforms and the Fabry disease program in a court-supervised auction.
/ 5 items
#SGMO↓
Sangamo Therapeutics Raises $25M Through New Stock Offering
Sangamo Therapeutics announces a $25 million stock and warrant offering to strengthen its finances and support general business needs.
FDA Fast-Tracks New Treatment for Chronic Nerve Pain
Sangamo Therapeutics (SGMO) receives FDA Fast Track designation for ST-503, a promising non-opioid treatment for small fiber neuropathy causing chronic pain.
Sangamo Moves Forward with Gene Therapy for Fabry Disease
Sangamo Therapeutics receives FDA approval to submit rolling application for ST-920, a one-time gene therapy treating Fabry disease, with accelerated review pathway granted.
FDA’s New Fast-Track Plan for Custom Gene Editing Could Transform Rare Disease Treatments
The FDA is unveiling a faster approval pathway for custom gene-editing therapies, aiming to spark major investment and accelerate cures for rare diseases through Crispr-based innovations.